Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)股票分析

$27.710

-1.349 (-4.87%)收盤時

Loading chart…
最高
28.905
開盤
28.850
成交量加權均價
27.97
成交量
9.83M
市值
4.30B
最低
27.300
成交金額
274.89M
企業價值/稅息折舊攤銷前利潤(TTM)
-18.31

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

AI 分析 of Hims & Hers Health Inc (HIMS)

持有

Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

估值指標

Hims & Hers Health Inc(HIMS)目前預期本益比為 73.53,5 年平均預期本益比為 18.51。

預期本益比

合理
5 年均值 P/E
18.51
目前P/E
73.53
高估
76.31
低估
-39.29

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.56
目前EV/EBITDA
-18.31
高估
46.27
低估
-19.15

預期股價營收比

合理
5 年均值 P/S
2.48
目前P/S
1.70
高估
3.53
低估
1.43

Alphio AI 對 HIMS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HIMS

$133.17

情境價格

基

基準

基準 · 50%HIMS

$111.56

情境價格

悲

悲觀

悲觀 · 25%HIMS

$85.01

情境價格

持有 HIMS 的大戶

B

BIT Capital GmbH

+ 持有HIMS

-3.90%

3個月報酬率

C

Casdin Capital, LLC

+ 持有HIMS

-4.80%

3個月報酬率

H

HANSAINVEST Hanseatische Investment-GmbH

+ 持有HIMS

-13.69%

3個月報酬率

W

Wolverine Asset Management, LLC

+ 持有HIMS

-15.57%

3個月報酬率

HIMS 常見問題 —— 由 Alphio AI 解答

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

jade_estuary2026/10/16

HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS

展開
dawn_badger2026/10/9

$HIMS The price is wasting time ... but it's running out of room. Imminent resolution. Weekly chart

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易